The UVA/PADOVA Type 1 Diabetes Simulator

Objective: Recent studies have provided new insights into nonlinearities of insulin action in the hypoglycemic range and into glucagon kinetics as it relates to response to hypoglycemia. Based on these data, we developed a new version of the UVA/PADOVA Type 1 Diabetes Simulator, which was submitted to FDA in 2013 (S2013). Methods: The model of glucose kinetics in hypoglycemia has been improved, implementing the notion that insulin-dependent utilization increases nonlinearly when glucose decreases below a certain threshold. In addition, glucagon kinetics and secretion and action models have been incorporated into the simulator: glucagon kinetics is a single compartment; glucagon secretion is controlled by plasma insulin, plasma glucose below a certain threshold, and glucose rate of change; and plasma glucagon stimulates with some delay endogenous glucose production. A refined statistical strategy for virtual patient generation has been adopted as well. Finally, new rules for determining insulin to carbs ratio (CR) and correction factor (CF) of the virtual patients have been implemented to better comply with clinical definitions. Results: S2013 shows a better performance in describing hypoglycemic events. In addition, the new virtual subjects span well the real type 1 diabetes mellitus population as demonstrated by good agreement between real and simulated distribution of patient-specific parameters, such as CR and CF. Conclusions: S2013 provides a more reliable framework for in silico trials, for testing glucose sensors and insulin augmented pump prediction methods, and for closed-loop single/dual hormone controller design, testing, and validation.

[1]  Y. Z. Ider,et al.  Quantitative estimation of insulin sensitivity. , 1979, The American journal of physiology.

[2]  E. Tsalikian,et al.  Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia. , 1984, The Western journal of medicine.

[3]  M. Laakso,et al.  Age of Onset and Type of Diabetes , 1985, Diabetes Care.

[4]  J. Ilonen,et al.  A comparison of childhood and adult type I diabetes mellitus. , 1989, The New England journal of medicine.

[5]  C Cobelli,et al.  Compartmental modeling of glucagon kinetics in the conscious dog. , 1995, Metabolism: clinical and experimental.

[6]  P. Fratino,et al.  IDDM in the Province of Pavia, Italy, From a Population-Based Registry: A descriptive study , 1995, Diabetes Care.

[7]  Martin Straume,et al.  Modeling Insulin-Glucose Dynamics during Insulin Induced Hypoglycemia. Evaluation of Glucose Counterregulation , 1999 .

[8]  Dynamic network model of glucose counterregulation in subjects with insulin-requiring diabetes. , 2000, Methods in enzymology.

[9]  Martin Straume,et al.  Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control of Insulin Dependent Diabetes , 2000 .

[10]  B. Ahrén,et al.  Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long‐term type 1 diabetes , 2002, Journal of internal medicine.

[11]  Karen M. Bolderman Putting Your Patients on the Pump , 2003 .

[12]  Roman Hovorka,et al.  Closing the loop: the adicol experience. , 2004, Diabetes technology & therapeutics.

[13]  W. Klitz,et al.  Genetic interaction among three genomic regions creates distinct contributions to early‐ and late‐onset type 1 diabetes mellitus , 2005, Pediatric diabetes.

[14]  F. Cerutti,et al.  Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. , 2005, Diabetes care.

[15]  L. Magni,et al.  Evaluating the Efficacy of Closed-Loop Glucose Regulation via Control-Variability Grid Analysis , 2008, Journal of diabetes science and technology.

[16]  Giovanni Sparacino,et al.  Diabetes: Models, Signals, and Control , 2009 .

[17]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[18]  L. Heinemann,et al.  Nonlinear Metabolic Effect of Insulin Across the Blood Glucose Range in Patients with Type 1 Diabetes Mellitus , 2010, Journal of diabetes science and technology.

[19]  Robert G. Sutherlin,et al.  A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes , 2010, Science Translational Medicine.

[20]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[21]  T. Jones,et al.  Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes , 2012, Diabetes Care.

[22]  Claudio Cobelli,et al.  Diurnal Pattern of Insulin Action in Type 1 Diabetes , 2013, Diabetes.

[23]  Marc D Breton,et al.  Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. , 2013, Diabetes technology & therapeutics.